Introduction
Electroconvulsive therapy (ECT) involves transcutaneous electrical stimulation of the cerebral cortex in order to induce a seizure like episode. The applications of ECT are predominantly rooted in refractory psychiatric illness, with efficacy documented medically refractory depression and schizophrenia 1, 2 .
The exact mechanism of action of ECT in the setting of psychiatric illness is poorly understood despite its long standing application [3] [4] [5] . It is theorized that ECT leads to alterations in neurotransmitter levels and an elevation in the seizure threshold post treatment. Increased gamma aminobutyric acid (GABA) mediate inhibition of action potential propagation has been suggested 3, 5 . Furthermore, the potential for a neuroendocrine mediated effect on neuronal function has been eluded to 6 . In the setting of seizure control utilizing ECT, the mechanism of action is even more elusive, though likely can be attributed to the above mentioned theories. The use of ECT in the treatment of SE/RSE has been mentioned only in reference to salvage therapies for super refractory status epilepticus (SRSE) 7, 8 . To date however there are only a small number of cases describing the use of ECT for SE/RSE [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Seizure 35 (2016) [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] A recent review in 2012 by Lambrecq et al. attempted to summarize the available literature on ECT in RSE utilizing a limited search 24 . This review displayed 11 cases based on the search strategy. However, the search excluded a large number of major health sciences databases and failed to evaluate the published meeting proceedings of the major relevant professional societies. Thus, there was the potential for missing some published reports on the subject. Our goal was to perform an extensive systematic review of the available literature on the use of ECT for RSE in order to better define its impact on seizure control.
Materials and methods
A systematic review using the methodology outlined in the Cochrane Handbook for Systematic Reviewers 25 was conducted.
The data was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 26 . The review questions and search strategy were decided upon by the primary author (FZ) and supervisor (CK).
Search question, population, inclusion and exclusion criteria
The question posed for systematic review was: What is the effectiveness of ECT for seizure control in SE/RSE? The definition of SE and RSE was as per the Neurocritical Care Society guidelines on the management of SE 27 . The term generalized refractory status epilepticus (GRSE) was used to refer to generalized tonic-clonic RSE. The term focal refractory status epilepticus (FRSE) was used to refer focal tonic-clonic RSE. The term multi-focal refractory status epilepticus (MFRSE) was used to refer to RSE that had a mutli-focal tonic-clonic nature. The term non-convulsive refractory status epilepticus (NCRSE) was used for non-convulsive seizures that fulfilled the criteria for RSE. Seizure cessation to ECT was defined as the absence of seizures for at least a 24 h period. All studies, prospective and retrospective of any size based on human subjects were included. The reason for an all-inclusive search was based on the small number of studies of any type identified by the primary author during a preliminary search of MEDLINE.
The primary outcome measure was electrographic seizure control, defined as: complete resolution, partial seizure reduction, and failure. This qualitative seizure response grading was used given the lack of detail around the electroencephalographic response reported within the studies found. Secondary outcome measures were patient outcome (if reported), and adverse events related to the use of ECT. Inclusion criteria were: All studies including human subjects whether prospective or retrospective, all study sizes, any age category, and the documented use of ECT for the purpose of seizure control in the setting of SE/RSE. Exclusion criteria were: animal and non-English studies.
Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, Healthstar, SCOPUS, and Cochrane Library from inception to August 2015 were searched using individualized search strategies for each database. The search strategy for MEDLINE can be seen in Appendix A of the supplementary material, with an identical search strategy utilized for the other databases. In addition, the World Health Organizations International Clinical Trials Registry Platform and ClinicalTrials.gov were searched looking for studies planned or underway, with none identified.
As well, meeting proceedings for the last 10 years looking for ongoing and unpublished work based on ECT for SE/RSE were Finally, reference lists of any review articles or systematic reviews on seizure management were reviewed for relevant studies on ECT application for SE/RSE that were missed during the database and meeting proceeding search.
Study selection
Utilizing two reviewers (FZ and MM), a two-step review of all articles returned by our search strategies was performed. First, the reviewers independently screened all titles and abstracts of the returned articles to decide if they met the inclusion criteria. Second, full text of the chosen articles was then assessed to confirm if they met the inclusion criteria and that the primary outcome of seizure control was reported in the study. Any discrepancies between the two reviewers were resolved by a third party (CK).
Data collection
Data was extracted from the selected articles and stored in an electronic database. Data fields included: patient demographics, type of study (prospective or retrospective), number of patients, type of ECT electrode used, stimulation parameters, timing to implementation of ECT, duration of ECT therapy, time to effect of ECT, how many other AED were utilized prior to implementation of ECT, degree of seizure control (as described previously), adverse effects, and patient outcome.
Patient outcome was graded according to the original Glasgow Outcome Scale (GOS) score, with a score of 1 indicating complete recovery and a score of 5 indicating death 35 .
Quality of evidence assessment
Assessment of the level of evidence for each included study was conducted by a panel of two independent reviewers, utilizing the Oxford criteria 28 and the Grading of Recommendation Assessment Development and Education (GRADE) criteria [29] [30] [31] [32] [33] [34] for level of evidence. We elected on utilizing two different systems to grade level of evidence given that these two systems are amongst the most commonly used. We believe this would allow a larger audience to follow our systematic approach in the setting of unfamiliarity with a particular grading system. The Oxford criteria consist of a 5 level grading system for literature. Level 1 is split into subcategories 1a, 1b, and 1c which represent a systematic review of randomized control trials (RCT) with homogeneity, individual RCT with narrow confidence interval, and all or none studies respectively. Oxford level 2 is split into 2a, 2b, and 2c representing systematic review of cohort studies with homogeneity of data, individual cohort study or low quality RCT, and outcomes research respectively. Oxford level 3 is split into 3a and 3b representing systematic review of case-control studies with homogeneity of data and individual case-control study respectively. Oxford level 4 represents case-series and poor cohort studies. Finally, Oxford level 5 represents expert opinion.
The GRADE level of evidence is split into 4 levels: A, B, C and D. GRADE level A represents high evidence with multiple high quality studies having consistent results. GRADE level B represents moderate evidence with one high quality study, or multiple low quality studies. GRADE level C evidence represents low evidence with one or more studies with severe limitations. Finally, GRADE level D represents very low evidence based on either expert opinion or few studies with severe limitations.
Any discrepancies between the grading of the two reviewers (FZ and MM)were resolved via a third party (CK).
Statistical analysis
A meta-analysis was not performed in this study due to the heterogeneity of data within the articles and the presence of a small number of low quality retrospective studies.
Results
The results of the search strategy are summarized in Fig. 1 . A total of 474 articles were identified, with 471 from the database search and 3 from published meeting proceedings. After removing duplicates, there were 351 articles. By applying the inclusion/ exclusion criteria to the title and abstract, we identified 28 articles with 35 from the database search and 3 from meeting proceedings. Applying the inclusion/exclusion criteria to the full text documents, 15 articles were eligible for inclusion in the systematic review, with 12 from database and 3 from meeting proceeding sources. The articles that were excluded were done so because they either did not report details around the application of ECT for seizure control in RSE, or because they were review articles. Reference sections from these review articles were searched for any other articles missed in the database search, with 0 being identified.
Of the 15 articles included in the review [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Across all studies, a total of 19 patients were documented as having received ECT for RSE (mean 1 patient/study; range: 1-3 patients/study). Four patients were pediatric with a mean age of 10 Table 2 .
ECT treatment characteristics
Twelve of the 14 original articles provided 9,10,12-18,20-22 details around the treatment parameters for ECT. The remaining 2 studies only referred to the use of ECT in the management of RSE, without providing treatment parameters 11, 19 .
Electrode position was bifrontotemporal in 4 patients 10,13 ,
''bilateral'' in 3 patients 17, 18, 20 , and mixed in 1 patient 15 . In eleven patients the electrode position for the ECT treatment was not described 9, 11, 12, 14, 16, 19, 21, 22 .
The number of treatment sessions with ECT was highly variable across the studies included in the review. The most commonly described session frequency was 1 per day. The most common treatment duration with ECT lasted approximately 1 week, with daily sessions.
Duration of treatment prior to implementation of ECT therapy was documented in 7 articles 9, 10, 13, 15, 16, 18, 20 , ranging from 9 to 103 days (mean = 40 days). The remaining 7 articles failed to mention the duration of therapy prior to implementation of ECT 11, 12, 14, 17, 19, 21, 22 . The number of AEDs administered prior to ECT was documented in all studies, with the total number ranging from 2 to 14 (mean = 7). Detailed ECT treatment characteristics can be seen in Table 2 . Looking at seizure subtype: 5 of the 9 (55.5%) GRSE patients responded, 4 of the 7 (57.1%) FRSE patients responded, and 2 of the 3 (66.6%) NCRSE patients responded.
Seizure response
The time from ECT response to recurrence of seizure activity was recorded in some studies. The duration of response to ECT therapy varied from 2 days up to 8 years. The most common duration of seizure control with ECT was 2 weeks to 3 months.
Adverse effects of ECT
Adverse events related to ECT therapy were documented in 4 studies 12, 13, 17, 18 . Two studies stated ''no adverse events'' were seen 17, 18 . Three patients had transient lethargy or amnestic events 12, 13 . No cardiac arrest or respiratory complications were reported. The remaining 10 studies did not document adverse events 9-11,14-16,19-22 .
Outcome
Outcome data was recorded in 10 of the 14 studies is a meeting abstract which contains the same patient data as Shin et al. 20 . Patient data from Shin et al. 23 was not included in the final data analysis in order to avoid duplication of data. Given the limited heterogeneous retrospective dataset formal statements on the association of ECT response to seizure characteristics cannot be made at this time.
Level of evidence for ECT in RSE
Based on the 14 original articles included in the final review, all fulfill Oxford level 4, GRADE D evidence to suggest a potential impact of ECT on seizure control in the setting of RSE.
Summary of the level of evidence can be seen in Table 3 .
Discussion
Through our systematic review we identified 14 original articles [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] A few important points can be seen within our review. First, the application of ECT appears to have an impacton seizure control in the setting of RSE within the series identified. Given the heterogeneity of the reports we are not able to compare the impact of ECT in these patients to other therapies. Furthermore, the exact treatment/stimulation parameters leading to seizure response were quite variable within the studies identified and thus we can comment on an appropriated treatment regimen at this time. This is in contrast to the previously published review on the subject from 2012, in which complete seizure cessation was documented at 80% 24 . Second, the anti-epileptic effect of ECT is present even in cases of prolonged seizure duration. Third, the reported duration of effect of ECT on seizure control was quite variable and difficult to interpret, with the most common therapeutic duration lasting from 2 weeks up to 3 months. Some patients required repeat treatment with ECT. This highlights the point that ECT will unlikely be a permanent solution to patients RSE, but more of a bridging therapy to allow for titration of AED regimens. As some patients would have been seen in outpatient follow up during some of these reported time frames, it is difficult to translate these values to the ''duration of effect'' for ECT in the setting of the acute management of RSE. WillECT need to become a part of outpatient therapy for these individuals with transient responses to stimulation? Based on current data available, it is unknown at this time. Fourth, a small number of transient complications were described, emphasizing the relative safety of this treatment. Finally, patient functional outcomes were poor with as GOS of 4 and 5 in 26.3% and 26.3% of patients. Only 15.8% of patients qualified for a GOS of 1 or 2. Six patients (31.5%) had insufficient data in the parent reports to accurately determine their GOS.
Our review has significant limitations that require recognition. First, the small number of studies identified, all with small patient populations, makes it difficult to generalize to all RSE. Second, the retrospective heterogeneous nature of the data makes it difficult to perform a meaningful meta-analysis. Third, the seizure response to ECT may not be related entirely to the stimulation at all, and may be a reflection of the combination of multiple AEDs and therapies working in concert. Fourth, our comments on the treatment regimen and stimulation parameters of ECT are limited given the small number of studies and heterogeneity of the described regimens. Finally, the potential for publication bias in the articles reviewed is high. It is likely that there are many more negative results with ECT for RSE that haven't made it to the literature.
Currently, the routine use of ECT for seizure control in RSE cannot be recommended at this time. The results of this review point to a potential impact that this therapy may have on seizure control, however further prospective study is warranted. There exists a need for international databases that document the impact of therapies in RSE, as they may the understanding of the impact of ECT on seizure control.
Conclusions
Oxford level 4, GRADE D evidence exists to suggest an improvement in seizure control with ECT application for RSE. Routine use of ECT cannot be recommended at this time. Further prospective study of this therapy is required in order to determine its efficacy in this setting.
